Feed Category: Vaccines & Cell Therapy

Vericel Corp (NASDAQ:VCEL), a leader in the field of regenerative medicine, has recently witnessed a significant insider sell by its President and CEO, Dominick Colangelo…. [Read More]

In this piece, we will take a look at the 12 best healthcare stocks for the long term. If you want to skip our overview… [Read More]

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about… [Read More]

By David Bautz, PhDNASDAQ:BCLIREAD THE FULL BCLI RESEARCH REPORTBusiness UpdateClear Path Forward for Phase 3b Trial of NurOwnOn December 7, 2023, BrainStorm Cell Therapeutics, Inc…. [Read More]

– Conference Call/Webcast Scheduled for Today at 4:30 PM ET -STONY BROOK, NY / ACCESSWIRE / December 7, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN)… [Read More]

Century Therapeutics IPSC announced FDA clearance of its investigational new drug (IND) application for CNTY-101 for an autoimmune and inflammatory disease indication. This IND clearance allows… [Read More]

Meeting Provided a Clear Path for Planned Phase 3b TrialNEW YORK, Dec. 7, 2023 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of… [Read More]

Bristol Myers Squibb BMY announced that the FDA has accepted its supplemental biologics license application (sBLA) for Opdivo (nivolumab) in combination with cisplatin-based chemotherapy as a first-line treatment… [Read More]

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Adma… [Read More]

(Adds background in paragraphs 2 to 4)Dec 5 (Reuters) – Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the… [Read More]

GAITHERSBURG, Md., Dec. 5, 2023 /CNW/ — Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health… [Read More]

Shares of Dynavax Technologies (DVAX) have gained 3% over the past four weeks to close the last trading session at $13.92, but there could still… [Read More]